#ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival
Novartis says its third-generation chronic myeloid leukemia drug — a scion to the fading blockbuster Gleevec — nearly doubled the response rate among patients who have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
